MX374396B - Rocio de fentanilo sublingual. - Google Patents

Rocio de fentanilo sublingual.

Info

Publication number
MX374396B
MX374396B MX2015000710A MX2015000710A MX374396B MX 374396 B MX374396 B MX 374396B MX 2015000710 A MX2015000710 A MX 2015000710A MX 2015000710 A MX2015000710 A MX 2015000710A MX 374396 B MX374396 B MX 374396B
Authority
MX
Mexico
Prior art keywords
sublingual fentanyl
fentanyl spray
sublingual
spray
formulations
Prior art date
Application number
MX2015000710A
Other languages
English (en)
Spanish (es)
Inventor
Linet Kattookaran
Neha N Parikh
S George Kottayil
Venkat R Goskonda
Zhongyuan Zhu
Original Assignee
Insys Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38309867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX374396(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Insys Therapeutics Inc filed Critical Insys Therapeutics Inc
Publication of MX374396B publication Critical patent/MX374396B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2015000710A 2006-01-25 2007-01-25 Rocio de fentanilo sublingual. MX374396B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76205706P 2006-01-25 2006-01-25
PCT/US2007/002163 WO2007087431A2 (en) 2006-01-25 2007-01-25 Sublingual fentanyl spray

Publications (1)

Publication Number Publication Date
MX374396B true MX374396B (es) 2025-03-06

Family

ID=38309867

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2015000710A MX374396B (es) 2006-01-25 2007-01-25 Rocio de fentanilo sublingual.
MX2008009522A MX2008009522A (es) 2006-01-25 2007-01-25 Rocio de fentanilo sublingual.
MX2020008616A MX2020008616A (es) 2006-01-25 2008-07-24 Rocio de fentanilo sublingual.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2008009522A MX2008009522A (es) 2006-01-25 2007-01-25 Rocio de fentanilo sublingual.
MX2020008616A MX2020008616A (es) 2006-01-25 2008-07-24 Rocio de fentanilo sublingual.

Country Status (16)

Country Link
US (6) US8486972B2 (enExample)
EP (2) EP2641595A1 (enExample)
JP (3) JP5241514B2 (enExample)
CN (1) CN101378735B (enExample)
AU (1) AU2007208229B2 (enExample)
BR (1) BRPI0707235B8 (enExample)
CA (1) CA2637672C (enExample)
DK (1) DK1976521T3 (enExample)
ES (1) ES2535233T3 (enExample)
MX (3) MX374396B (enExample)
NZ (1) NZ569949A (enExample)
PL (1) PL1976521T3 (enExample)
PT (1) PT1976521E (enExample)
RU (1) RU2432950C2 (enExample)
SI (1) SI1976521T1 (enExample)
WO (1) WO2007087431A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001281746C1 (en) * 2000-07-31 2010-09-09 ISTITUTO GENTILI S.r.l. Fentanyl composition for nasal administration
PT1976521E (pt) 2006-01-25 2015-06-09 Insys Therapeutics Inc Aerossol sublingual de fentanilo
US8210167B2 (en) * 2007-03-02 2012-07-03 Corbco, Inc. Manually operated monodose nasal sprayer
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
PT2180844T (pt) * 2007-08-02 2018-04-06 Insys Dev Co Inc Nebulizador sub-lingual de fentanilo
GB0720967D0 (en) * 2007-10-25 2007-12-05 Protophama Ltd Anti-material pharmaceutical composition
PL2244737T3 (pl) * 2008-01-22 2020-05-18 The Board Of Regents Of The University Of Texas System Kompozycje lotnego środka znieczulającego zawierające rozpuszczalniki ekstrakcyjne do znieczulania miejscowego i / albo zwalczania bólu
US20090286832A1 (en) * 2008-05-15 2009-11-19 Kiichiro Nabeta Narcotic emulsion formulations for treatment of surgical pain
CN102333443A (zh) * 2009-02-26 2012-01-25 帝国制药美国公司 治疗癌症疼痛的麻醉乳液制剂
MY167918A (en) * 2009-04-23 2018-09-27 Londonpharma Ltd Composition for use in the sublingual delivery of medicaments to humans
GB2469792A (en) * 2009-04-23 2010-11-03 Calvin John Ross Oil-based pharmaceutical formulation for sublingual delivery
US20110021588A1 (en) * 2009-05-15 2011-01-27 Recro Pharma, Inc. Sublingual dexmeditomidine compositions and methods of use thereof
US20120214874A1 (en) * 2009-08-26 2012-08-23 Nuvo Research Inc. Pharmaceutical formulations and methods of use
NZ600358A (en) * 2009-11-23 2014-05-30 Cipla Ltd Topical foam composition
WO2011073985A1 (en) * 2009-12-14 2011-06-23 Coeruleus Ltd. Compositions and methods of counteracting residual sedative effects of sleep/ hypnotic drugs
GB2481728B (en) * 2010-06-30 2012-05-23 Londonpharma Ltd Formulations and delivery devices for the sublingual administration of opioids
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
GB2487007B (en) * 2012-03-19 2013-06-05 Londonpharma Ltd COC containers and delivery devices for the sublingual administration of opioids
US9839611B2 (en) 2013-09-10 2017-12-12 Insys Development Company, Inc. Sublingual buprenorphine spray
US9918981B2 (en) 2013-09-10 2018-03-20 Insys Development Company, Inc. Liquid buprenorphine formulations
US9867818B2 (en) 2013-09-10 2018-01-16 Insys Development Company, Inc. Sublingual buprenorphine spray
CA2923811C (en) * 2013-09-10 2021-07-27 Insys Pharma, Inc. Sublingual buprenorphine spray
US9956166B2 (en) 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
US9566233B2 (en) 2013-11-14 2017-02-14 Insys Development Company, Inc. Ondansetron sublingual spray formulation
US20160199294A1 (en) * 2014-07-08 2016-07-14 Insys Development Company, Inc. Sublingual naloxone spray
CA2954370A1 (en) * 2014-07-08 2016-01-14 Insys Pharma, Inc. Sublingual naloxone spray
US9855234B2 (en) * 2014-07-08 2018-01-02 Insys Development Company, Inc. Diclofenac sublingual spray
US10441538B2 (en) * 2014-07-08 2019-10-15 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10617686B2 (en) * 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10722510B2 (en) * 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US9517307B2 (en) 2014-07-18 2016-12-13 Kaleo, Inc. Devices and methods for delivering opioid antagonists including formulations for naloxone
US10172833B2 (en) 2015-08-11 2019-01-08 Insys Development Company, Inc. Sublingual ondansetron spray
KR102395342B1 (ko) * 2016-04-13 2022-05-10 보드 오브 리젠츠 오브 디 유니버시티 오브 네브라스카 레시니페라톡신을 사용한 투여 방법 및 심혈관 질환을 치료하는 방법
US20170340557A1 (en) * 2016-05-27 2017-11-30 Insys Development Company, Inc. Sublingual fentanyl formulations containing a permeation enhancer
US9650338B1 (en) 2016-07-29 2017-05-16 VDM Biochemicals, Inc. Opioid antagonist compounds and methods of making and using
CA3166250A1 (en) * 2020-02-05 2021-08-12 Gregory G. Plucinski Drug products for intranasal administration and uses thereof
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244478A (en) 1979-06-27 1981-01-13 Mpl, Inc. Closure assembly for unit dose vial
GB8900267D0 (en) 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
US5219083A (en) 1992-04-02 1993-06-15 Sterling Winthrop Inc. Stopper for reduction of particulate matter
EP0713386B1 (en) 1993-08-10 1998-11-18 The Boots Company PLC Spray formulation having a cooling effect
DE19536245A1 (de) 1994-09-30 1996-04-04 Juergen Dr Regenold Pharmazeutische Zusammensetzung
US20030095926A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20040136914A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20050281752A1 (en) 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20030082107A1 (en) 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US20030190286A1 (en) 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US20030095925A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20030095927A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US20050180923A1 (en) 1997-10-01 2005-08-18 Dugger Harry A.Iii Buccal, polar and non-polar spray containing testosterone
US20040141923A1 (en) 1997-10-01 2004-07-22 Dugger Harry A. Buccal, polar and non-polar spray containing alprazolam
EP1029536B1 (en) 1997-10-01 2007-11-28 Novadel Pharma Inc. Buccal non-polar spray
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20040136915A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
US20090162300A1 (en) 1997-10-01 2009-06-25 Dugger Iii Harry A Buccal, polar and non-polar spray containing alprazolam
US20050287075A1 (en) 1997-10-01 2005-12-29 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20030077228A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20030185761A1 (en) 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20050163719A1 (en) 1997-10-01 2005-07-28 Dugger Harry A.Iii Buccal, polar and non-polar spray containing diazepam
US20040136913A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing sumatriptan
US20030077229A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20050002867A1 (en) 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
SE9803239D0 (sv) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
WO2000047203A1 (en) 1999-02-12 2000-08-17 Mqs, Inc. Formulation and system for intra-oral delivery of pharmaceutical agents
US20030190290A1 (en) * 2000-06-22 2003-10-09 Calvin Ross Pharmaceutical compositions
US20020160991A1 (en) 2000-12-04 2002-10-31 Liming Shao Orally-bioavailable formulations of fentanyl and congeners thereof
WO2003045357A1 (en) 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
US8992974B2 (en) * 2003-02-24 2015-03-31 Pharmaceuticals Productions, Inc. Transmucosal drug delivery system
EP1608372A2 (en) * 2003-03-11 2005-12-28 Arakis Ltd. Compositions containing fentanyl
GB0305579D0 (en) * 2003-03-11 2003-04-16 Dallas Burston Ltd Pharmaceutical compositions
US20060062812A1 (en) * 2003-03-11 2006-03-23 Calvin Ross Novel compositions
GB0514043D0 (en) 2005-07-08 2005-08-17 Arakis Ltd Fentanyl formulation
US20070124554A1 (en) * 2005-10-28 2007-05-31 Honeywell International Inc. Global memory for a rapidio network
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
PT1976521E (pt) 2006-01-25 2015-06-09 Insys Therapeutics Inc Aerossol sublingual de fentanilo
PT2180844T (pt) 2007-08-02 2018-04-06 Insys Dev Co Inc Nebulizador sub-lingual de fentanilo

Also Published As

Publication number Publication date
ES2535233T3 (es) 2015-05-06
JP5241514B2 (ja) 2013-07-17
BRPI0707235B8 (pt) 2021-05-25
CN101378735A (zh) 2009-03-04
BRPI0707235B1 (pt) 2020-04-14
MX2020008616A (es) 2020-09-21
US8835460B2 (en) 2014-09-16
US20170202820A1 (en) 2017-07-20
US20160193142A1 (en) 2016-07-07
RU2008130763A (ru) 2010-02-27
JP2013056928A (ja) 2013-03-28
EP1976521B1 (en) 2015-03-11
US10016403B2 (en) 2018-07-10
JP5630877B2 (ja) 2014-11-26
AU2007208229B2 (en) 2009-11-05
WO2007087431A3 (en) 2008-09-25
US20180303813A1 (en) 2018-10-25
EP1976521A2 (en) 2008-10-08
US9289387B2 (en) 2016-03-22
PT1976521E (pt) 2015-06-09
JP2013127003A (ja) 2013-06-27
BRPI0707235A2 (pt) 2011-04-26
JP2009528272A (ja) 2009-08-06
SI1976521T1 (sl) 2015-06-30
WO2007087431A2 (en) 2007-08-02
EP2641595A1 (en) 2013-09-25
CA2637672A1 (en) 2007-08-02
EP1976521A4 (en) 2010-11-03
MX2008009522A (es) 2009-01-07
US20130327321A1 (en) 2013-12-12
CA2637672C (en) 2012-07-24
CN101378735B (zh) 2013-04-03
PL1976521T3 (pl) 2015-10-30
DK1976521T3 (en) 2015-04-27
NZ569949A (en) 2011-10-28
US8486972B2 (en) 2013-07-16
RU2432950C2 (ru) 2011-11-10
US9642797B2 (en) 2017-05-09
US20070261695A1 (en) 2007-11-15
US20140343100A1 (en) 2014-11-20
AU2007208229A1 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
MX374396B (es) Rocio de fentanilo sublingual.
WO2009017837A3 (en) Sublingual fentanyl spray
AP2037A (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
HUS1500034I1 (hu) Indolidon-származékok fibrózisos betegségek kezelésére vagy megelõzésére
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
HK1211475A1 (en) Combination therapy
DK2023918T3 (da) Cyclosporiner til behandlingen og forebyggelse af okulære lidelser
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
PH12014500386A1 (en) Combination treatment for hepatitis c
MY145795A (en) Pyrazoline compounds
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
WO2009041663A1 (ja) 皮膚疾患の予防及び／または治療剤
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament
MX2012008509A (es) Agente terapeutico o profilactic para enfermedades del tracto biliar.
TW200626158A (en) Naphthaline derivatives
IL191928A0 (en) Triazoloanilinopyrimidine derivatives for use as antiviral agents
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
WO2007081808A3 (en) Compounds and derivatives for the treatment of medical conditions by modulating hormone-sensitive lipase activity
PL1612210T3 (pl) Nowe analogi nitrobenzylotioinozyny
WO2007144889A3 (en) Treatment of neurofibromatosis
EA200802000A1 (ru) Фармацевтически приемлемые соли и полиморфные формы
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
NO20090448L (no) En aminoisoquinolin trombin inhibitor med forbedret biotilgjengelighet
LV14230A (lv) Farmaceitiska kompozīcija Parkinsona slimības profilaksei un ārstēšanai